Infectious Diseases
Randomized trial: Tocilizumab does not improve outcomes for patients hospitalized with Covid-19
22 Oct, 2020 | 09:42h | UTCEfficacy of Tocilizumab in Patients Hospitalized with Covid-19 – New England Journal of Medicine
Amid pandemic, U.S. has seen 300,000 ‘excess deaths,’ with highest rates among people of color
22 Oct, 2020 | 09:41h | UTC
Commentary on Twitter
A new @CDCMMWR estimates since January 2020, 299,000 more people have died than the typical number during the same weeks in previous years. At least 2 out of 3 excess deaths were attributed to #COVID19. Learn more: https://t.co/fg4W6u4e3C. pic.twitter.com/i9TDxrBrTV
— CDC (@CDCgov) October 20, 2020
Will Covid-19 vaccines save lives? Current trials aren’t designed to tell us
22 Oct, 2020 | 09:40h | UTCWill covid-19 vaccines save lives? Current trials aren’t designed to tell us – The BMJ
Commentaries: COVID-19 vaccine trials won’t tell us if the shots save lives, expert notes – CNN AND Coronavirus vaccine trials won’t tell us if they save lives, prevent serious illness or stop transmission – here’s why – The Conversation
Commentary on Twitter
The world is waiting on a vaccine for covid-19 that will reduce the likelihood of getting severely ill and prevent infection. Yet the current phase III trials are not actually set up to prove either, finds Peter Doshi https://t.co/BSb9WiUQXo
— The BMJ (@bmj_latest) October 21, 2020
New calculator predicts risk of hospital admission and mortality from coronavirus 19 in adults
22 Oct, 2020 | 09:37h | UTCSee calculator: QCovid® risk calculator
Commentary on Twitter
A new "living" high quality prediction model for #COVID19 risk for hospitalization and mortality: top 20% risk accounted for 94% of deaths; https://t.co/aPXRM2pHCq calculatorhttps://t.co/gdd8b3j33K @bmj_latest
by @AshClift @JuliaHCox @OxPrimaryCare and colleagues pic.twitter.com/s8TrWWECb0— Eric Topol (@EricTopol) October 21, 2020
SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates
22 Oct, 2020 | 09:36h | UTCSARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates – The Lancet
Commentary: The COVID-19 vaccine pipeline – News Medical
Commentary on Twitter
NEW Review—G Poland, I Ovsyannikova & R Kennedy @MayoClinic discuss what is currently known about human humoral & cellular immune responses to SARS-CoV-2 & relate this knowledge to the #COVID19 vaccines currently in phase 3 clinical trials https://t.co/eDkFq4WStA pic.twitter.com/hfw6yjviym
— The Lancet (@TheLancet) October 14, 2020
Perspective: Immunity and Re-Infection
22 Oct, 2020 | 09:34h | UTCImmunity and Re-Infection – Science Translational Medicine
Video consultations in primary and specialist care during the covid-19 pandemic and beyond
21 Oct, 2020 | 09:30h | UTCVideo consultations in primary and specialist care during the covid-19 pandemic and beyond – The BMJ
Studies offer little hope for Tocilizumab in treating COVID
21 Oct, 2020 | 09:27h | UTCStudies offer little hope for tocilizumab in treating COVID – CIDRAP
See studies: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 – JAMA Internal Medicine AND Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine AND Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine
Commentary: expert reaction to three studies of Tocilizumab to treat COVID patients – Science Media Centre
Related study (preprint): Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv
Dozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials
21 Oct, 2020 | 09:25h | UTCDozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials – Nature
Commentaries: U.K. Preparing COVID-19 Vaccine Trials That Deliberately Expose Study Subjects – NPR AND UK plan to be first to run human challenge Covid trials – BBC
Studies point to big drop in COVID-19 death rates
21 Oct, 2020 | 09:23h | UTCStudies Point To Big Drop In COVID-19 Death Rates – NPR
‘Super antigens’ tied to mysterious COVID-19 syndrome in children
21 Oct, 2020 | 09:21h | UTC‘Super antigens’ tied to mysterious COVID-19 syndrome in children – National Geographic
Viewpoint – COVID-19, children and non-communicable diseases: Translating evidence into action
21 Oct, 2020 | 09:19h | UTC
Commentary on Twitter
"The recognition that NCDs are a massive contributor to COVID-19 mortality and severe illness across all age groups should be a wake-up call to accelerate preventive strategies for NCDs."
New piece on how children & youth are affected by #COVID19 & #NCDshttps://t.co/oXV6UAdgGL pic.twitter.com/WNTZtVAztZ
— Marie Hauerslev (@HauerslevMarie) October 17, 2020
Perspective: COVID-19 in children and young people
21 Oct, 2020 | 09:17h | UTCCOVID-19 in children and young people – Science
Updated Guideline: Coronavirus (COVID-19) infection in pregnancy
21 Oct, 2020 | 09:16h | UTCCoronavirus (COVID-19) Infection in Pregnancy – Royal College of Obstetricians & Gynaecologists
Clinical Report: Evaluation and management of the infant exposed to HIV in the US
21 Oct, 2020 | 09:09h | UTCEvaluation and Management of the Infant Exposed to HIV in the United States – Pediatrics
Commentaries: Pediatrics Group Updates Guidelines on Managing HIV-Exposed Infants – NEJM Journal Watch AND Perinatal Exposure to HIV Requires Specialized, Coordinated Care – AJMC
WHO takes a position on genetically modified mosquitoes
21 Oct, 2020 | 09:02h | UTCWHO takes a position on genetically modified mosquitoes – World Health Organization
Position Statement: Evaluation of genetically modified mosquitoes for the control of vector-borne diseases – World Health Organization
Covid-19: The global crisis — in data
20 Oct, 2020 | 01:45h | UTCCovid-19: The global crisis — in data – Financial Times
Herd immunity and implications for SARS-CoV-2 control
20 Oct, 2020 | 01:44h | UTCHerd Immunity and Implications for SARS-CoV-2 Control – JAMA
Author Interview: Can We Count on Herd Immunity to Control COVID-19? – JAMA
Patient Page: What Is Herd Immunity? – JAMA
Commentary on Twitter
Herd immunity is real. It may be inevitable given our poor handling of COVID-19 and nature of the virus.
But to *deliberately* shoot for natural herd immunity (ie, without a vaccine) makes no sense.
Via @SaadOmer3 @InciYildirim11 @thehowie @JAMA_current https://t.co/PwWc1wMMzE pic.twitter.com/Ybn7vHFnt8
— Nicholas A. Christakis (@NAChristakis) October 19, 2020
Editorial: Covid-19’s known unknowns
20 Oct, 2020 | 01:42h | UTCCovid-19’s known unknowns – The BMJ
Commentary on Twitter
If you are going to read anything today let it be this short editorial @bmj_latest https://t.co/ggvEglehJm pic.twitter.com/hyw21BcZBU
— Maarten van Smeden (@MaartenvSmeden) October 19, 2020
Opinion: The scientific and ethical feasibility of immunity passports
20 Oct, 2020 | 01:41h | UTCThe scientific and ethical feasibility of immunity passports – The Lancet Infectious Diseases
Related: Digital ‘health passport’ trials under way to aid reopening of borders – The Guardian
Covid-19 vaccine protocols reveal that trials are designed to succeed
20 Oct, 2020 | 01:40h | UTCCovid-19 Vaccine Protocols Reveal That Trials Are Designed To Succeed – Forbes
Perspective: All eyes on a hurdle race for a SARS-CoV-2 vaccine
20 Oct, 2020 | 01:39h | UTCAll eyes on a hurdle race for a SARS-CoV-2 vaccine – Nature
Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?
20 Oct, 2020 | 01:38h | UTC
Commentary on Twitter
Side effect of #COVID19 surge: ignoring well established strategies
➡️ limit ABTs exposure vs resistances: MV/long #ICU stay
➡️ avoid toxicity: antivirals/antibiotics can have severe adverse effects/interactions
➡️ high mortality: improving outcome crucial https://t.co/FN3LtKKlsr pic.twitter.com/7KGbIOH3Uf— Intens Care Med (@yourICM) October 17, 2020
Meta-analysis: The association of D-dimers with mortality, intensive care unit admission or ARDS in patients hospitalized with COVID-19
20 Oct, 2020 | 01:37h | UTC
The household secondary attack rate of SARS-CoV-2: A rapid review
20 Oct, 2020 | 01:36h | UTCThe household secondary attack rate of SARS-CoV-2: A rapid review – Clinical Infectious Diseases
Commentary on Twitter
Household secondary attack rate (SAR) of #SARSCoV2 A rapid review https://t.co/u2YGZYB9Zt The overall pooled random-effects estimate of the household SAR was 17.1% (95% CI: 13.7-21.2%). Household SAR higher among older adult contacts and among contacts of symptomatic cases.
— Carlos del Rio (@CarlosdelRio7) October 16, 2020